Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Savara (SVRA – Research Report) and Zentalis Pharmaceuticals ...

Zentalis Pharmaceuticals LLC shares tumbled to a 52-week low, touching down at $1.76, as the biopharmaceutical company grapples with a challenging market environment. According to InvestingPro ...

The posters can be accessed through the “Supporting Publications” tab on the “Our Approach” section of the Zentalis website at the time of each presentation’s starting session.

(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL) announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

(MENAFN- GlobeNewsWire - Nasdaq) Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data ...

"Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of ...

$371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis ® ...

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...